Rehab G Khalil1, Adel Abdel-Moneim2, Ahmed I Yousef3, Hanan Abdel-Rahman4, Mohamed I Zanaty4, Amr El-Sayed4. 1. Immunology Division, Faculty of Science, Beni-Suef University, Beni Suef, Egypt. 2. Molecular Physiology Division, Faculty of Science, Beni-Suef University, Salah Salim St., Beni Suef, 62511, Egypt. adel_men2020@yahoo.com. 3. Molecular Physiology Division, Faculty of Science, Beni-Suef University, Salah Salim St., Beni Suef, 62511, Egypt. 4. Biotechnology and Life Sciences Department, Faculty of Postgraduate Studies for Advanced Science, Beni-Suef University, Beni Suef, Egypt.
Abstract
BACKGROUND: In type 1 diabetes mellitus (T1DM), cytokines have a central role in orchestrating multicellular relations between β-cells and immune cells. This study aims to investigate the role of interleukin (IL)-21, IL-23, and IL-2, and their association with dyslipidemia in T1DM children. METHODS: The sample population consisted of 30 healthy controls and 70 children with T1DM, the latter of which were split into two groups according to the duration of their T1DM diagnosis: recent (≤ 1 year; n = 21) and older (> 1 year; n = 49) diagnoses. RESULTS: Fasting blood sugar and glycated hemoglobin levels in all diabetic children were significantly (P < 0.001) higher, whereas levels of plasma C-peptide were markedly (P < 0.001) lower in children with T1DM compared to healthy controls. In older T1DM diagnosis children, the levels of creatinine were noticeably (P < 0.05) increased relative to healthy controls. In all diabetic children, levels of total triglyceride, cholesterol, and low-density lipoprotein were increased significantly (P < 0.001) than those of healthy controls. Furthermore, the IL-21 and IL-23 mRNA expressions of all children with T1DM were elevated significantly (P < 0.001) relative to healthy controls, whereas IL-2 levels revealed a significant (P < 0.001) decrease in all diabetic children. CONCLUSION: There was a synergistic interplay between IL-21 and IL-23 with an antagonistic action of IL-2 in T1DM patients, and all three interleukins were associated with dyslipidemia in diabetic children. Importantly, therapies targeting IL-21 and IL-23 are promising targets for preventive strategies against the development of T1DM and its complications.
BACKGROUND: In type 1 diabetes mellitus (T1DM), cytokines have a central role in orchestrating multicellular relations between β-cells and immune cells. This study aims to investigate the role of interleukin (IL)-21, IL-23, and IL-2, and their association with dyslipidemia in T1DM children. METHODS: The sample population consisted of 30 healthy controls and 70 children with T1DM, the latter of which were split into two groups according to the duration of their T1DM diagnosis: recent (≤ 1 year; n = 21) and older (> 1 year; n = 49) diagnoses. RESULTS: Fasting blood sugar and glycated hemoglobin levels in all diabetic children were significantly (P < 0.001) higher, whereas levels of plasma C-peptide were markedly (P < 0.001) lower in children with T1DM compared to healthy controls. In older T1DM diagnosis children, the levels of creatinine were noticeably (P < 0.05) increased relative to healthy controls. In all diabetic children, levels of total triglyceride, cholesterol, and low-density lipoprotein were increased significantly (P < 0.001) than those of healthy controls. Furthermore, the IL-21 and IL-23 mRNA expressions of all children with T1DM were elevated significantly (P < 0.001) relative to healthy controls, whereas IL-2 levels revealed a significant (P < 0.001) decrease in all diabetic children. CONCLUSION: There was a synergistic interplay between IL-21 and IL-23 with an antagonistic action of IL-2 in T1DM patients, and all three interleukins were associated with dyslipidemia in diabetic children. Importantly, therapies targeting IL-21 and IL-23 are promising targets for preventive strategies against the development of T1DM and its complications.
Authors: Helen M McGuire; Alexis Vogelzang; Cindy S Ma; William E Hughes; Pablo A Silveira; Stuart G Tangye; Daniel Christ; David Fulcher; Marika Falcone; Cecile King Journal: Immunity Date: 2011-04-22 Impact factor: 31.745
Authors: L V d'Uscio; T A Baker; C B Mantilla; L Smith; D Weiler; G C Sieck; Z S Katusic Journal: Arterioscler Thromb Vasc Biol Date: 2001-06 Impact factor: 8.311
Authors: Elena Myasoedova; Cynthia S Crowson; Hilal Maradit Kremers; Veronique L Roger; Patrick D Fitz-Gibbon; Terry M Therneau; Sherine E Gabriel Journal: Ann Rheum Dis Date: 2011-01-07 Impact factor: 19.103
Authors: G Luck; H Liao; N J Murray; H R Grimmer; E E Warminski; M P Williamson; T H Lilley; E Haslam Journal: Phytochemistry Date: 1994-09 Impact factor: 4.072
Authors: Alexis Vogelzang; Helen M McGuire; Di Yu; Jonathan Sprent; Charles R Mackay; Cecile King Journal: Immunity Date: 2008-07-03 Impact factor: 31.745
Authors: Ricardo C Ferreira; Henry Z Simons; Whitney S Thompson; Antony J Cutler; Xaquin Castro Dopico; Deborah J Smyth; Meghavi Mashar; Helen Schuilenburg; Neil M Walker; David B Dunger; Chris Wallace; John A Todd; Linda S Wicker; Marcin L Pekalski Journal: Diabetologia Date: 2015-02-06 Impact factor: 10.122